SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
SAB Biotherapeutics, listed on Nasdaq as SABS, announced upcoming oral and poster presentations highlighting new clinical and mechanistic data on SAB-142, their lead immunotherapy candidate for newly diagnosed Stage 3 type 1 diabetes (T1D). The data showcase SAB-142's multi-specific binding profile and potential as a best-in-class disease-modifying…